CytoMed Therapeutics (GDTC) Total Non-Current Liabilities (2021 - 2025)
CytoMed Therapeutics (GDTC) posted Total Non-Current Liabilities of $325696.2 for Q4 2025, down 24.57% sequentially from $431769.0 in Q2 2025, and up 3.81% YoY from $313744.9 in Q4 2024.
CytoMed Therapeutics (GDTC) Total Non-Current Liabilities (2021 - 2025) Analysis & Trends
CytoMed Therapeutics has reported Total Non-Current Liabilities for 5 years, with the latest figure at $325696.2 in Q4 2025.
- Quarterly Total Non-Current Liabilities rose 3.81% year-over-year to $325696.2 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $325696.2 (up 3.81% YoY) and the FY2025 annual result came in at $328266.0, up 5.07% from the prior year.
- Total Non-Current Liabilities retreated to $325696.2 in Q4 2025 per GDTC's latest filing, from $431769.0 in the prior quarter.
- Over five years, Total Non-Current Liabilities peaked at $431769.0 in Q2 2025 and troughed at $302033.6 in Q4 2023.
- A 5-year average of $368318.3 and a median of $366774.6 in 2022 frame the typical range for Total Non-Current Liabilities.
- The sharpest annual moves came in 2022 and 2025: Total Non-Current Liabilities fell 16.13% in 2022, then grew 10.46% in 2025.
- Over 5 years, Total Non-Current Liabilities stood at $408558.5 in 2021, then fell by 16.13% to $342653.2 in 2022, then decreased by 11.85% to $302033.6 in 2023, then grew by 3.88% to $313744.9 in 2024, then climbed by 3.81% to $325696.2 in 2025.
- According to Business Quant data, Total Non-Current Liabilities over the past three periods registered $325696.2, $431769.0, and $313744.9 for Q4 2025, Q2 2025, and Q4 2024 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Non-Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 5.92 Bn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 7.74 Bn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 40.00 Mn |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 3.92 Bn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 1.88 Bn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | 724.15 Mn |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 1.17 Bn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 9.32 Bn |
| 10 | CytoMed Therapeutics | 10.72 Mn | 9.11 Mn | - | 325,696.18 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 325,696.18 |
| Jun 30, 2025 | 431,769.00 |
| Dec 31, 2024 | 313,744.88 |
| Jun 30, 2024 | 390,896.00 |
| Dec 31, 2023 | 302,033.65 |
| Jun 30, 2023 | 431,195.00 |
| Dec 31, 2022 | 342,653.15 |
| Dec 31, 2021 | 408,558.52 |